Background/Aims: The present study investigates the effects of pregabalin (PGB), acetaminophen (ACET) and tenoxicam (TNX) administration in somatic and visceral nociception, using the tail flick test and the writhing test in mice. Methods: In the tail flick test, the substances were administered orally and the latency time response was recorded 15, 30, 60, 90 and 120 min after administration. In the writhing test, pain responses were scored every 5 min during a 30-min period after intraperitoneal injection of diluted acetic acid. Results: Our study demonstrated that oral administration of the combination PGB-ACET resulted in a stronger increase of latency reaction - statistically significant after 15 min compared to TNX and after 30 min compared to PGB in tail flick test. In the writhing test, the combination PGB-ACET, but also PGB-TNX, resulted in a stronger decrease of writhe numbers - statistically significant compared to the effects of the separate administration of each substance. This decrease was more intense in animals treated with the combination PGB-ACET than with PGB-TNX. Conclusion: These results suggest an antinociceptive activity which may be a consequence of the synergic action of the substances.

Keywords:
Pregabalin, Analgesic combinations, Tail flick test, Writhing test
1.
Guay DRP: Pregabalin in neuropathic pain: a more ‘pharmaceutically elegant' gabapentin? Am J Geriatr Pharmacother 2005;3:274-287.
2.
Gajraj NM: Pregabalin: its pharmacology and use in pain management. Anesth Analg 2007;105:1805-1815.
3.
Baldwin DS, Ajel K, Masdrakis VG, Nowak M, Rafiq R: Pregabalin for the treatment of generalized anxiety disorder: an update. Neuropsychiatr Dis Treat 2013;9:883-892.
4.
Anderson GD: Understanding the ramifications of switching around AEDS: what are the data? Johns Hopkins Advanced Studies in Medicine. Somerville, Galen, 2008, vol 8, pp 229-234.
5.
Rastegariyanzadeh R, Meimandi MSh, Heravi G: Evaluation of antinociceptive effect of pregabalin in mice and its combination with tramadol using tail-flick test. Res Pharm Sci 2012;7:499-517.
6.
Raptis E, Vadalouca A, Stavropoulou E, Argyra E, Melemeni A, Siafaka I: Pregabalin versus opioids for the treatment of neuropathic cancer pain: a prospective, head-to-head, randomized, open-label study. Pain Pract 2014;14:32-42.
7.
Zacny JP, Paice JA, Coalson DW: Subjective, psychomotor, and physiological effects of pregabalin alone and in combination with oxycodone in healthy volunteers. Pharmacol Biochem Behav 2012;100:560-565.
8.
Raffa RB, Pergolizzi JV, Segarnick DJ, Tallarida RJ: Oxycodone combinations for pain relief. Drugs Today (Barc) 2010;46:379-398.
9.
Mathiesen O, Rasmussen ML, Dierking G, Lech K, Hilsted KL, Fomsgaard JS, Lose G, Dahl JB: Pregabalin and dexamethasone in combination with paracetamol for postoperative pain control after abdominal hysterectomy. A randomized clinical trial. Acta Anaesthesiol Scand 2009;53:227-235.
10.
Kis B, Snipes JA, Busija D: Acetaminophen and the cyclooxygenase-3 puzzle: sorting out facts, fictions, and uncertainties. J Pharmacol Exp Ther 2005;315:1-7.
11.
Ong CK, Seymour RA, Lirk P, Merry AF: Combining paracetamol (acetaminophen) with nonsteroidal anti-inflammatory drugs: a qualitative systematic review of analgesic efficacy for acute postoperative pain. Anesth Analg 2010;110:1170-1179.
12.
Nilsen OG: Clinical pharmacokinetics of tenoxicam. Clin Pharmacokinet 1994;26:16-43.
13.
Gunusen I, Karaman S, Acar A, Sargin A, Firat V: The efficacy of paracetamol versus tenoxicam on postoperative pain and morphine consumption after abdominal hysterectomy: a placebo-controlled, randomized study. Clin Exp Obstet Gynecol 2012;39:49-52.
14.
Cevik E, Cinar O, Salman N, Bayir A, Arziman I, Ardic S, Youngquist ST: Comparing the efficacy of intravenous tenoxicam, lornoxicam, and dexketoprofen trometamol for the treatment of renal colic. Am J Emerg Med 2012;30:1486-1490.
15.
Arslan H, Topcuoglu HS, Aladag H: Effectiveness of tenoxicam and ibuprofen for pain prevention following endodontic therapy in comparison to placebo: a randomized double-blind clinical trial. J Oral Sci 2011;53:157-161.
16.
Chang WK, Wu HL, Yang CS, Chang KY, Liu CL, Chan KH, Sung CS: Effect on pain relief and inflammatory response following addition of tenoxicam to intravenous patient-controlled morphine analgesia: a double-blind, randomized, controlled study in patients undergoing spine fusion surgery. Pain Med 2013;14:736-748.
17.
Luszczki JJ: Dose-response relationship analysis of pregabalin dose and their antinociceptive effects in hot-plate test in mice. Pharmacol Rep 2010;62:942-948.
18.
Mogil JS: Animal models of pain: progress and challenges. Nat Rev Neurosci 2009;10:283-294.
19.
Ma C: Animal models of pain. Int Anesthesiol Clin 2007;45:121-131.
20.
Le Bars D, Gozariu M, Cadden SW: Animal models of nociception. Pharmacol Rev 2001;53:597-652.
21.
Keefe FJ, Fillingim RB, Williams DA: Behavioral assessment of pain: nonverbal measures in animals and humans. ILAR J 1991;33:3-13.
22.
Walker EA, Butelman ER, DeCosta BR: Opioid thermal antinociception in rhesus monkeys: receptor mechanisms and temperature dependency. J Pharmacol Exp Ther 1993;267:280-286.
23.
Gawade SP: Acetic acid induced painful endogenous infliction in writhing test on mice. J Pharmacol Pharmacother 2012;3:348.
24.
Shin JW, Hwang KS, Kim YK Leem JG, Lee C: Nonsteroidal anti-inflammatory drugs suppress pain-related behaviors, but not referred hyperalgesia of visceral pain in mice. Anaesth Analg 2006;102:195-200.
25.
Zimmerman M: Ethical guidelines for investigations of experimental pain in conscious animals. Pain 1983;16:109-110.
26.
Idid SZ, Saad LB, Yaacob H, Shahimi MM: Evaluation of analgesia induced by mitragynine, morphine and paracetamol on mice. ASEAN Review of Biodiversity and Environmental Conservation (ARBEC) Evaluation of Analgesics on Mice 1998, article 4, pp 1-7.
27.
Chesler EJ, Ritchie J, Kokayeff A, Lariviere WR, Wilson SG, Mogil JS: Genotype-dependence of gabapentin and pregabalin sensitivity: the pharmacogenetic mediation of analgesia is specific to the type of pain being inhibited. Pain 2003;106:325-335.
28.
Takenchi Y, Takasu K, Ono H, Tanabe M: Pregabalin S-(+)-3-isobutylgaba activates the descending noradrenergic system to alleviate neuropathic pain in mouse partial sciatic nerve ligation model. Neuropharmacology 2007;53:842-853.
29.
Meymand MS, Keyhanfar F: Relative potency of pregabalin, gabapentin and morphine in a mouse model of visceral pain. Can J Anesth 2013;60:44-49.
30.
Sikandar S, Dickenson AH: Pregabalin modulation of spinal and brainstem visceral nociceptive processing. Pain 2011;152:2312-2322.
31.
Rajesh M, Mohapatra S, Swain TR: Comparative analysis of effect of pregabalin, amitriptyline and lamotrigine in streptozotocin induced diabetic peripheral neuropathy in albino rats. Int J Pharmacol Toxicol Sci 2011;1:16-23.
32.
Hurley RW, Chaterjea D, Rosefeng M, Taylor CP, Hammond DL: Gabapentin and pregabalin can interact synergistically with naproxen to produce antihyperalgesia. Anesthesiology 2002;97:1263-1273.
33.
Meymand MS, Keyhandfar F: Pregabalin antinociception and its interaction with tramadol in acute model of pain. Pharmacol Rep 2012;64:576-585.
34.
Luszczki JJ, Florek-Luszczki M: Synergistic interaction of pregabalin with the synthetic cannabinoid WIN 55,212 mesylate in the hot plate test in mice: an isobolographic analysis. Pharmacol Rep 2012;64:723-732.
35.
Keyhanfar F, Meymandi MS, Sepehri G, Rastegaryanzadeh R, Heravi G: Evaluation of antinociceptive effect of pregabalin in mice and its combination with tramadol using tail-flick test. Iran J Pharm Res 2013;12:483-493.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.